Featured Research

from universities, journals, and other organizations

Gene Expression Pattern Predicts Response In Advanced Bowel Cancer

Date:
October 24, 2008
Source:
ECCO-the European CanCer Organisation
Summary:
Research has shown for the first time that identifying patterns of gene expression can be used to predict response to treatment in patients with advanced metastatic colorectal cancer.

Research by scientists in France has shown for the first time that identifying patterns of gene expression can be used to predict response to treatment in patients with advanced metastatic colorectal cancer.

Dr Maguy Del Rio, a scientist at the Institut de Recherche en Cancιrologie de Montpellier (Montpellier, France), presented a study to the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva October 22 [1] in which she and her team had identified an 11-gene signature that could be used to separate those patients who would respond to a particular chemotherapy (FOLFIRI – leucovorin, fluorouracil and irinotecan) from those who would not. FOLFIRI is one of the most commonly used, first-line treatments for metastatic colorectal cancer.

Dr Del Rio said: "Gene expression signatures are a new class of molecular diagnostic tests for cancer. For cancer prognosis, three tests are commercially available, all for breast cancer. It is more difficult to predict responses to anticancer drugs than it is to predict prognosis. Few studies have been made in this field. This and our previous study[2] are the first that demonstrate the utility of gene expression profiling for the prediction of response in colorectal patients."

About half of patients with colorectal cancer develop liver metastases during the course of their disease. Dr Del Rio said: "When this happens, it is critical for the success of overall treatment to chose a chemotherapy regime that is most likely to induce a maximal response during the first course of treatment. It is a major clinical challenge to identify a subset of patients who could benefit from a particular chemotherapy, and to identify those who will not and therefore need to be treated using an alternative treatment."

The researchers used microarray analysis to identify gene expression levels in samples taken from 19 colorectal cancer patients with liver metastases who had not yet started chemotherapy. They followed the patients to see who responded to the chemotherapy and who did not, and, using this information, found a pattern of 11 genes that clearly separated responder and non-responder patients. They designed a mathematical model that was able to predict and classify the eight responding and 11 non-responding patients with 100% accuracy.

Dr Del Rio said: "The fact that we achieved 100% accuracy could be due to our small sample size of 19 patients. Obviously, it is essential to validate and, if necessary, to improved the gene signature in a larger independent cohort of patients. Until it is properly validated, the gene signature cannot be used in the clinic. However, in the future it could be used to identify a subset of patients would could benefit from chemotherapy and lead to an improvement in response to metastatic treatment for colorectal cancer.

"For the subset of patients who are identified as non-responders to FOLFIRI, other treatments such as FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy, or newer, targeted drugs such as cetuximab and bevacizumab could be added."

At present, the test for the 11-gene signature takes about three days to run, with several steps involved: surgical removal of tumour tissue, histologic validation, RNA extraction, chip hybridization, comparative analysis of gene expression and patient's classification. The researchers hope that this process could be speeded up, but the ability to choose the correct first-line treatment is a big step forward.

"For patients with metastatic colorectal cancer, time is an important factor and to make the good first-line treatment choice could be decisive in the overall success of the treatment," said Dr Del Rio.

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer

Institute], AACR [American Association for Cancer Research].

[2] Del Rio et al., J Clin Oncol. 2007 1;25(7):773-80).


Story Source:

The above story is based on materials provided by ECCO-the European CanCer Organisation. Note: Materials may be edited for content and length.


Cite This Page:

ECCO-the European CanCer Organisation. "Gene Expression Pattern Predicts Response In Advanced Bowel Cancer." ScienceDaily. ScienceDaily, 24 October 2008. <www.sciencedaily.com/releases/2008/10/081022073726.htm>.
ECCO-the European CanCer Organisation. (2008, October 24). Gene Expression Pattern Predicts Response In Advanced Bowel Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/10/081022073726.htm
ECCO-the European CanCer Organisation. "Gene Expression Pattern Predicts Response In Advanced Bowel Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/10/081022073726.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins